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ABSTRACT: Many mitochondrial metabolites and bioactive molecules contain two carboxylic acid moieties that make them unable
to cross biological membranes. Hence, there is considerable interest in facilitating the uptake of these molecules into cells and
mitochondria to modify or report on their function. Conjugation to the triphenylphosphonium (TPP) lipophilic cation is widely
used to deliver molecules selectively to mitochondria in response to the membrane potential. However, permanent attachment to the
cation can disrupt the biological function of small dicarboxylates. Here, we have developed a strategy using TPP to release
dicarboxylates selectively within mitochondria. For this, the dicarboxylate is attached to a TPP compound via a single ester bond,
which is then cleaved by intramitochondrial esterase activity, releasing the dicarboxylate within the organelle. Leaving the second
carboxylic acid free also means mitochondrial uptake is dependent on the pH gradient across the inner membrane. To assess this
strategy, we synthesized a range of TPP monoesters of the model dicarboxylate, malonate. We then tested their mitochondrial
accumulation and ability to deliver malonate to isolated mitochondria and to cells, in vitro and in vivo. A TPP−malonate monoester
compound, TPP11−malonate, in which the dicarboxylate group was attached to the TPP compound via a hydrophobic undecyl link,
was most effective at releasing malonate within mitochondria in cells and in vivo. Therefore, we have developed a TPP−monoester
platform that enables the selective release of bioactive dicarboxylates within mitochondria.
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■ INTRODUCTION
Mitochondria are essential for a wide range of cellular
processes, and mitochondrial dysfunction plays a critical role
in the pathology of numerous diseases.1−3 Consequently, there
is considerable interest in targeting molecules selectively to
these organelles to report on and modify mitochondrial
processes.1,4 To do this, a molecule is often targeted using a
delivery vector that selectively accumulates within mitochon-
dria.5−9 A common approach is by conjugation to the
lipophilic triphenylphosphonium (TPP) cation, which is
membrane permeable and drives the selective accumulation
of attached moieties within mitochondria in cells and in
vivo.6,10,11 TPP cations achieve >100−1000-fold accumulation
within mitochondria due to their uptake driven by the large
mitochondrial membrane potential, as well as the potential
across the plasma membrane.6,10−12 This approach has been
used extensively to target a range of probe and drug molecules
to mitochondria in vivo, providing both new insights into
mitochondrial biology and potential therapies.8,13−18
The inner mitochondrial membrane (IMM) presents a
significant barrier to the delivery of charged molecules to
mitochondria and possesses only a limited number of
mitochondrial transporter proteins.19 However, the large
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membrane potential (Δψm) across the IMM (140−180 mV
negative inside) is exploited by the TPP cation and uptake
occurs according to the Nernst equation; hence, there is a 10-
fold accumulation per ∼60 mV of Δψm.4,12 While the positive
charge on the phosphorus atom favors its accumulation into
mitochondria in a Nernstian fashion, it also presents a problem
when partitioning into the hydrophobic mitochondrial
membrane. This is due to the large activation energy needed
to remove the aqueous solvation shell for movement of the ion
into the hydrophobic membrane core (Born energy).12,20
Image forces and dipole interactions with the phospholipid
esters also hinder TPP uptake; however, these contribute far
less than the Born energy.12,20 By introducing hydrophobic
phenyl groups, the charge is spread over a larger area, and
steric hindrance distances the water molecules from the
charge; thus, the solvent-accessible charge is lower, and the
free energy required to remove water molecules for
partitioning into the membrane is reduced.12,21
Usually the drug or probe for delivery to mitochondria is
permanently attached to the TPP cation.16,18,22−24 However, a
permanent attachment is not always appropriate, as the bulky
TPP moiety may interfere with the biological activity of the
molecule. To overcome this, the TPP can be conjugated to its
cargo by a cleavable linker, enabling the small molecule to
remain in the organelle while the TPP delivery module
redistributes. This approach has been used to deliver lipoic
Figure 1. Mitochondria-targeted delivery strategy for the dicarboxylate malonate. (A) Theoretical uptake and hydrolysis of TPP−malonate
monoesters in mitochondria. Abbreviations: OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; IMS, intermembrane
space; SDH, succinate dehydrogenase; Δψm, mitochondrial membrane potential. (B−E) Structures of TPP−malonate monoesters synthesized (B)
and hydrolysis schemes for TPP3−malonate (C), TPP6−malonate (D), and TPP11−malonate (E).
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acid to mitochondria by attaching it via an ester link that was
cleaved within mitochondria by an endogenous esterase, which
was proposed to be aldehyde dehydrogenase 2 (ALDH2).25
Additionally, an S-nitrosothiol was attached to TPP, which was
reduced within mitochondria, releasing nitric oxide.8,26 There
are many small bioactive molecules, including key mitochon-
drial substrates, that contain two carboxylic acid functions
whose biological activity would be blocked by conjugation to
TPP. Therefore, here, we set out to develop a cleavable TPP
vector to deliver bioactive dicarboxylates to mitochondria.
One approach to deliver dicarboxylic acids to mitochondria
is by linking one carboxylic acid to TPP by a cleavable ester,
while also masking the other carboxylate as an ester to
neutralize the carboxylate’s negative charge at biological pH
values. However, even though its mitochondrial accumulation
may be favorable, the two ester bonds required to be cleaved to
release the active compound would have different hydrolysis
properties and thus create uncertainty in drug delivery. Instead,
we focused on linking the dicarboxylate to TPP by a single
ester, while leaving the other carboxylate free (Figure 1A). In
addition to requiring only a single ester cleavage, this approach
may enhance the overall mitochondrial uptake (∼4−10 fold)
because the uptake of weak acids, such as carboxylates, into
mitochondria is favored by the pH gradient between the
cytosol (pH ∼7.2) and mitochondrial matrix (pH ∼8).27,28
This suggests that a dicarboxylate attached to a TPP cation by
a single ester linkage should effectively deliver a dicarboxylate
to mitochondria (Figure 1A); however, it is unclear if this
approach would be effective in cells or in vivo.
To assess this targeting strategy, we chose the simple
dicarboxylate malonate as our test compound. In addition to
being chemically simple, malonate is a competitive inhibitor of
succinate dehydrogenase (SDH)29,30 and can inhibit the
succinate-driven production of reactive oxygen species
(ROS) by reverse electron transfer (RET) through mitochon-
drial complex I.31,32 This production of ROS is dependent on
succinate availability to SDH, which can be prevented by the
delivery of malonate, enabling this delivery to be assessed.31,33
We found that this mitochondria-targeted strategy could
deliver malonate to mitochondria, provided that the linker
between TPP and malonate was hydrophobic enough to
counteract the polarity of the free carboxylic acid and thus
enable membrane permeation. Here, we show that a TPP−
undecyl monoester of malonic acid (TPP11−malonate)
accumulated in mitochondria in response to the proton motive
force, releasing malonate within mitochondria in cells and in
vivo. Thus, we have established a general procedure for the
selective and enhanced delivery of dicarboxylates to
mitochondria in cells and in vivo.
■ EXPERIMENTAL SECTION
Materials. Cell culture materials (Gibco branded) were
purchased from Thermo Fisher Scientific. All other materials
were purchased from Sigma-Aldrich, unless otherwise stated.
Synthesis of TPP−Malonate Monoesters. Detailed
chemical synthesis of the TPP−malonate monoesters is
provided in the Supporting Information.
Maintenance of Cells in Culture. C2C12 and HeLa cells
were obtained from American Type Culture Collection
(ATCC). Both were maintained at 37 °C, 5% CO2 and
100% humidity in DMEM media (4.5 g/L of glucose, 1 mM
sodium pyruvate, 2 mM Glutamax, 1.5 g/L of sodium
bicarbonate) supplemented with 10% Fetal Bovine Serum
(FBS), 100 U/mL of penicillin and 100 mg/mL of
streptomycin.
Animals. All procedures were carried out in accordance
with the United Kingdom (UK) Animals (Scientific
Procedures) Act of 1986 and the University of Cambridge
Animal Welfare Policy under project licenses 70/8702, 70/
8238, and 70/7963, reviewed by the University of Cambridge
Animal Welfare Ethical Review Board. Wistar rats (female,
10−12 weeks, ∼250 g) and C57BL/6J mice (male, 8−12
weeks, ∼25 g) were obtained from Charles River Laboratories
UK (Margate, UK). Both were maintained with ad libitum
access to laboratory chow and water. Animals were culled by
cervical dislocation with accordance to UK Home Office
Schedule 1 procedures.
Isolation of Rat Liver and Heart Mitochondria. Rat
heart and liver mitochondria were isolated as described
previously.16,34 Briefly, the tissue was washed with STE buffer
(250 mM sucrose, 5 mM Tris-Cl, 1 mM EGTA; pH 7.4, 4 °C)
or STEB buffer for hearts (STE + 0.1% (w/v) bovine serum
albumin (BSA)) and minced finely. The minced tissue was
homogenized in a Dounce homogenizer in the relevant buffer
and centrifuged (1000 g, 5 min, 4 °C). The resulting
supernatant (for hearts, the supernatant was filtered through
pre-wet muslin) was centrifuged to pellet mitochondria (10000
g, 10 min, 4 °C). The mitochondrial pellet was resuspended in
buffer and recentrifuged under the same conditions to pellet
mitochondria, and the process was repeated. The final
mitochondrial pellet for all tissues was resuspended in STE
buffer (no BSA) and assayed for the protein concentration by a
bicinchoninic acid (BCA) assay (Thermo Fisher Scientific,
UK).
Preparation of Bovine Heart Mitochondrial Mem-
branes. Bovine heart mitochondria were isolated by differ-
ential centrifugation, as described previously.35 To prepare
membranes, bovine heart mitochondria were blended with
Milli-Q water (4 °C) before adding KCl (150 mM final
concentration) and were further blended until homogeneous.
The suspension was centrifuged (13500 g, 40 min, 4 °C), the
pellet homogenized in resuspension buffer (20 mM Tris-Cl, 1
mM EDTA, 10% (v/v) glycerol, pH 7.55 at 4 °C), and protein
concentration determined by a BCA assay.
Measuring Complex II + III Activity. Complex II + III
activity was measured as described previously.36 Bovine heart
mitochondrial membranes (80 μg of protein/mL) were
incubated in potassium phosphate buffer (50 mM potassium
phosphate, 1 mM EDTA, pH 7.4, 4 °C) supplemented with
KCN (3 mM), rotenone (4 μg/mL), and succinate. In a 96-
well microplate, compounds and a membrane incubation
solution were plated and incubated (15 min, 37 °C) ± porcine
liver esterase (PLE; 1 mg of protein/mL). Oxidized
cytochrome c was added prior to measuring the respiratory
chain activity by following the reduction of cytochrome c
spectrophotometrically at 550 nm (20 s intervals for 5 min, 30
°C; Spectramax Plus 384, Molecular Devices, UK). Final
concentrations of bovine heart mitochondrial membranes (10
μg of protein/well), cytochrome (30 μM), inhibitor (100 μM),
and succinate (1 mM) were used.
LC-MS/MS Analysis of Malonate. LC-MS/MS measure-
ment of malonate was performed using an LCMS-8060 mass
spectrometer (Shimadzu, UK) with a Nexera UHPLC system
(Shimadzu, UK), as described previously.31 Samples were
stored in a refrigerated autosampler (4 °C) until injection of 5
μL into a 15 μL flowthrough needle. A SeQuant ZIC-HILIC
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column (3.5 μm, 100 Å, 150 × 2.1 mm, 30 °C column
temperature; Merck Millipore, UK) with a ZIC-HILIC guard
column (200 Å, 1 × 5 mm) was used for liquid
chromatography. A flow rate of 0.2 mL/min was used with
mobile phases of (A) 10 mM ammonium bicarbonate (pH
unchanged) and (B) 100% acetonitrile. A gradient of 0−0.1
min, 80% MS buffer B; 0.1−4 min, 80−20% MS buffer B; 4−
10 min, 20% MS buffer B; 10−11 min, 20−80% MS buffer B;
and 11−15 min, 80% MS buffer B was used. The mass
spectrometer was operated in negative ion mode with multiple
reaction monitoring (MRM), and spectra were acquired using
Labsolutions software (Shimadzu, UK), with malonate levels
calculated from a standard curve in MS extraction buffer (50%
(v/v) methanol, 30% (v/v) acetonitrile, and 20% (v/v) MS-
grade water) compared to 1 nmol of MS internal standard
(13C3-malonate).
LC-MS/MS Analysis of TPP−Malonate Monoesters.
For TPP−malonate monoesters, separation was achieved using
an I-class Acquity ultra-performace liquid chromatography
(UPLC) ethylene bridge hybrid (BEH) C18 column (1 × 50
mm, 1.7 μm; Waters, UK) with a Waters UPLC filter (0.2 μm;
Waters, UK). A flow rate of 150 μL/min was used with mobile
phases of (C) 0.1% (v/v) formic acid in 100% water and (D)
0.1% (v/v) formic acid in 100% acetonitrile. A gradient of 0−
0.3 min, 5% D; 0.3−3 min, 5−100% D; 3−4 min, 100% D;
4.0−4.10 min, 100−5% D; 4.10−6.00 min, 5% D was used.
The mass spectrometer was operated in the positive ion mode
with multiple reaction monitoring (MRM), and spectra were
acquired using Labsolutions software (Shimadzu), with
compound quantities calculated from relevant standard curves
in MS extraction buffer compared to a 100 pmol MS internal
standard (d15-3-OH propyl-TPP).
RP-HPLC-UV Analysis of TPP−Malonate Monoesters.
RP-HPLC-UV was used for the characterization of TPP-linked
compounds, as described previously.37 Samples were prepared
in 1 mL volumes in 25% (v/v) acetonitrile + 0.1% (v/v)
trifluoroacetic acid (TFA) and filtered using a 0.22 μm syringe-
driven filter unit (Merck Millipore, UK). Then, 800 μL of
filtrate was loaded into a 2 mL sample loop, and compounds
were separated using a Jupiter 300 Å C18 RP-HPLC column
(Phenomenex, UK) attached to a Widepore C18 guard column
(Phenomenex, UK) using a Gilson 321 pump (Gilson, UK).
Compounds were eluted using a gradient elution with a mobile
phase composition consisting of HPLC buffer (A) 0.1% (v/v)
trifluoroacetic acid (TFA) in water and HPLC buffer (B) 0.1%
(v/v) TFA in acetonitrile. Compounds were eluted at a flow
rate of 1 mL/min with a gradient of 0−2 min, 5% B; 2−17
min, 5−100% B; 17−19 min, 100% B; and 19−22 min, 100−
5% B, and the UV absorbance was detected at 220 nm with a
Gilson 151 UV−vis spectrophotometer (Gilson, UK).
Hydrolysis of TPP−Malonate Monoesters. TPP−
malonate monoesters (200 μM) and the internal standard
(IS; isoamyl-TPP or propyl-TPP; 200 μM) were incubated in
KCl buffer (120 mM KCl, 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1 mM ethylene
glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
(EGTA); pH 7.2 or 8, 37 °C) on a shaking heatblock (1000
rpm; Eppendorf, UK). Then, 20 μL samples were taken at time
points of 0, 1, 2, 4, 8, and 24 h; extracted in 250 μL of HPLC
buffer B; diluted with 750 μL of HPLC buffer A; and filtered
and analyzed by UV-HPLC. For enzymatic hydrolysis, the KCl
buffer (pH 7.2) was supplemented with porcine liver esterase
(1 mg of protein/mL), and additional time points at 15 and 30
min were taken.
Mitochondrial Uptake of TPP−Malonate Monoesters.
Rat liver (RLM) or heart (RHM) mitochondria (0.5 mg of
protein/mL) were incubated in 2 mL of KCl buffer (pH 7.2,
37 °C) supplemented with TPP−malonate monoesters and an
internal control (propyl-TPP or isoamyl-TPP to avoid
retention time overlap) (5 μM each) in a shaking heatblock
(1000 rpm; Eppendorf, UK). Mitochondria were energized
with glutamate and malate (5 mM each). The uptake was
assessed at 5, 10, and 15 min of incubation. Where 2-[2-[4-
(trifluoromethoxy)phenyl]hydrazinylidene]-propanedinitrile
(FCCP) (1 μM), nigericin (100 nM) or tetraphenylborate (5
μM) were used, these were added at the beginning of the 5
min incubations. After an appropriate incubation time, samples
were rapidly cooled on ice before pelleting mitochondria by
centrifugation (10000 g, 5 min, 4 °C). Then, 750 μL of the
supernatant was extracted in 250 μL of HPLC buffer B and
filtered and analyzed by UV-HPLC. The mitochondrial pellet
was dried with tissue paper and extracted with 250 μL of
HPLC buffer B while vortexing, and then centrifuged (17000 g,
10 min, 4 °C). The resulting supernatant was diluted with 750
μL of HPLC buffer A and filtered before analyzing by UV-
HPLC.
Measurement of H2O2 Production in Isolated Heart
Mitochondria. ROS production by RET was measured by
following the conversion of Amplex Red to resorufin. Isolated
RHM were incubated in a KCl buffer supplemented with
Amplex Red (12.5 μM; Invitrogen, Thermo Fisher Scientific),
BSA (200 μg/mL), superoxide dismutase (40 μg/mL),
horseradish peroxidase (20 μg/mL), succinate (5 mM), and
compound (10 μM) or rotenone (4 μg/mL) in a 96-well plate.
Resorufin fluorescence was detected by λex= 570 nm and λem=
585 and calibrated against known concentrations of hydrogen
peroxide (46.6 M−1 cm−1 at 240 nm).
Incubation of Cells with TPP−Malonate Monoesters.
C2C12 or HeLa cells were plated in 6-well plates (300000
cells/well) and adhered overnight. The following day, the cell
culture medium was replaced with fresh medium (DMEM +
10% FBS) containing TPP11−malonate (10 μM) and
incubated for 0−240 min prior to extracting. Parallel plates
were incubated under the same conditions and used to
determine protein levels by a BCA assay (Thermo Fisher
Scientific, UK).
After incubation, cells and supernatant were extracted for
LC-MS/MS analysis. The supernatant was removed and
centrifuged (17000 g, 10 min, 4 °C) before adding 50 μL of
the resulting supernatant to 750 μL of a MS extraction buffer
(50% (v/v) methanol, 30% (v/v) acetonitrile, and 20% (v/v)
water) containing a MS internal standard (1 nmol 13C3-
malonate and 100 pmol d15-3-OH propyl-TPP). Cells were
washed 4 times with ice-cold PBS before 500 μL of the MS
extraction buffer containing the MS internal standard was
added to each well and incubated for 15 min on dry ice. Cells
were scraped into microcentrifuge tubes and, together with the
supernatant samples, were agitated (1200 rpm, 15 min, 4 °C)
before incubating at −20 °C for 1 h. Samples were centrifuged
twice to remove pelleted debris (17000 g, 10 min, 4 °C), and
the resulting supernatant was analyzed by LC-MS/MS.
In Vivo Delivery of TPP11−Malonate Monoester.
TPP11−malonate (1.6 mg/kg) was administered to C57BL/
6J mice via a 100 μL tail vein bolus injection in 0.9% saline.
Mice were culled either 5 or 40 min after injection, and the
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Figure 2. Malonate release from TPP−malonate monoesters. (A−D) TPP−malonate monoesters and internal control (isoamyl-TPP for TPP3 and
TPP6−malonate or propyl-TPP for TPP11−malonate) were incubated in the KCl buffer with PLE (1 mg of protein/mL) for up to 24 h and TPP-
containing compounds measured by RP-HPLC-UV at 220 nm. Peak areas from each sample were normalized to the peak area of the internal
control and presented as a percentage of the peak area of the initial parent compound (mean ± SEM, n = 3). An expanded view of early time points
of the TPP11−malonate incubation from panel C is presented in panel D. (E) SDH inhibition by TPP−malonate monoesters. BHMMs (80 μg of
protein/mL) were incubated with the vehicle control (0.1% EtOH) or TPP−malonate monoesters (100 μM) ± PLE (1 mg of protein/mL) with
succinate (1 mM) for 15 min before measuring complex II + III activity by observing the reduction of ferricytochrome c (30 μM)
spectrophotometrically at 550 nm (mean ± SEM % of vehicle control activity, n = 3). The statistical significance was assessed by two-way ANOVA
with Tukey’s correction for multiple comparisons (between +PLE and −PLE), where *p < 0.05 and ****p < 0.0001.
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Figure 3. Mitochondrial accumulation and malonate delivery by TPP−malonate monoesters. TPP−malonate monoesters (5 μM) and internal
control (5 μM; isoamyl-TPP for TPP3− and TPP6−malonate or propyl-TPP for TPP11−malonate to avoid retention time overlap) were incubated
with energized RLM or RHM (0.5 mg of protein/mL) ± FCCP (1 μM) before pelleting mitochondria, extracting the pellet and supernatant, and
analyzing by RP-HPLC-UV at 220 nm. (A) Representative RP-HPLC-UV traces of TPP−malonate monoesters in pelleted rat heart mitochondria
of 3 biological replicates. (B−C) Quantification of TPP-containing species peak areas in the mitochondrial pellet of (B) RHM and (C) RLM
(mean ± SEM, n = 3). Statistical significance was assessed by two-way ANOVA with Dunnett’s correction for multiple comparisons (compared to
the relevant control group), where *p < 0.05, ***p < 0.001, and ****p < 0.0001. (D) 11-OH undecyl-TPP levels in the mitochondrial pellet or
supernatant after 5, 10, or 15 min of incubation with TPP11−malonate. (E) Mitochondrial malonate delivery. The energized RLM or RHM (0.5 mg
of protein/mL) were incubated with TPP−malonate monoesters (10 μM) for 5 min before analyzing the mitochondrial pellet malonate levels by
LC-MS/MS (mean ± SEM, n = 3). The statistical significance was assessed by two-way ANOVA with Bonferroni’s correction for multiple
comparisons, where ****p < 0.0001. (F) Inhibition of ROS production from RET by TPP−malonate monoesters. RHM were incubated with
mitochondria-targeted malonate monoesters (10 μM) or rotenone (0.5 μM; rotenone inhibits mitochondrial complex I, thus abolishing RET), and
RET was initiated by the addition of succinate (5 mM). ROS from RET were measured as the conversion of Amplex Red to resorufin by
fluorescence at excitation at 570 nm and emission at 580 nm. H2O2 production from RET was measured by interpolation from a H2O2 standard
curve under the same conditions (mean ± SEM, n = 3). The statistical significance was assessed by one-way ANOVA with Dunnett’s correction for
multiple comparisons, where *p < 0.05.
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organs were harvested and snap frozen in liquid nitrogen. TPP-
containing compounds and malonate were extracted from
tissues by homogenizing tissue (40 mg of wet weight/mL) in
the MS extraction buffer containing the MS internal standard
(1 nmol of 13C3-malonate and 100 pmol of d15-3-OH propyl-
TPP) in a Precellys 24 tissue lyser (6500 rpm, 15 s × 2; Bertin
Instruments, France) using CK-28R homogenizing tubes
(Bertin Instruments, France). Homogenized samples were
stored at −20 °C for 1 h before being centrifuged twice to
remove the pelleted debris (17000 g, 10 min, 4 °C), and the
resulting supernatant was analyzed by LC-MS/MS.
Statistical Analysis, Randomization, and Blinding.
Data in figures are presented as the mean ± standard error of
the mean (SEM) unless indicated in the figure legend. The
statistical analysis was assessed by one- or two-way ANOVA
followed by the appropriate post hoc correction for multiple
comparisons or, where two groups were assessed, an unpaired
two-tailed Student’s t test. A p value <0.05 was considered
significant. Statistics were calculated in Prism 8.4 software
(Graphpad Software Inc., USA). Randomization and blinding
were carried out where possible: in vivo samples were
processed for extraction blindly, and all mass spectrometry
samples were randomized and analyzed blindly.
Data Availability. The data corresponding to the
synthesized compounds are available at 10.5525/gla.
researchdata.1031. Data supporting the findings in this study
will be made available upon reasonable request to the
corresponding authors.
■ RESULTS
TPP−Malonate Monoester Prodrugs for Mitochon-
drial Delivery. The delivery of dicarboxylate molecules to
mitochondria is of interest due to their central role in
metabolism and their contribution to many pathologies.1−3
While endogenous transport mechanisms for dicarboxylates
exist, these are limited by substrate specificity and thus may be
unsuitable for rationally designed small molecule dicarboxylate
drugs. Furthermore, to achieve mitochondrial delivery, two
endogenous uptake mechanisms must be present and also
facilitate rapid uptake into mitochondria, without metabolism
of the drug in the cytosol. To overcome this, we thought to
conjugate a small molecule dicarboxylate to the TPP
mitochondria-targeting moiety to overcome the many bio-
logical barriers to the delivery of dicarboxylates.
Previous work had shown that TPP-linked weak acids have
increased mitochondrial uptake due to their steady-state
accumulation being driven by both the membrane potential
and pH gradient between the cytosol and mitochondrial matrix
(Figure 1A).27,28 Although the carboxylic acid enhances end-
point uptake, it decreases the membrane permeability and thus
the rate of uptake. Therefore, to enable the mitochondrial
uptake, any TPP conjugate that includes a carboxylic acid will
likely need increased overall hydrophobicity to counteract the
polarity of its carboxylic acid group.27,28 Therefore, we
synthesized three TPP−malonate monoesters with a range of
hydrophobicities using alkyl linkers of increasing lengths:
propyl, hexyl, and undecyl (TPP3−malonate, TPP6−malonate,
and TPP11−malonate, respectively) (Figures 1B and S1). Each
molecule contained an ester bond attaching the TPP linker to
malonate, which once hydrolyzed should release malonate and
its corresponding TPP alcohol (Figure 1C−E).
Hydrolysis of TPP−Malonate Monoesters In Vitro.
Using a RP-HPLC method to detect the TPP−alcohol
products of ester hydrolysis (Figure S2), we demonstrated
that all the TPP−malonate monoesters were stable at pH 7.2
or 8 for up to 24 h (Figure S3). To test if the TPP−malonate
monoesters could be cleaved enzymatically, we used porcine
liver esterase (PLE), which is widely used as a surrogate for
intracellular esterases.38−40 The hydrolysis rates depended
dramatically on the alkyl linker length (Figure 2A−D). While
TPP11−malonate was completely hydrolyzed by PLE within 1
h, it took 24 h to hydrolyze ∼80% of TPP6−malonate, and the
hydrolysis of TPP3−malonate was negligible. As hydrolysis of
the TPP−malonate monoesters should also release malonate,
an inhibitor of SDH, we measured the effect of the compounds
on the SDH activity of bovine heart mitochondrial membranes
(BHMMs) treated with PLE. This showed that PLE treatment
of TPP11−malonate, and to a lesser extent TPP6−malonate,
could inhibit SDH activity but TPP3−malonate could not
(Figure 2E). The slight inhibitory effect of TPP11−malonate in
the absence of PLE is due to the interaction of the
hydrophobic TPP compound with the membrane, as similarly
seen with 11-OH undecyl-TPP alone (Figure S3G).21,41
The difference in the rate of hydrolysis between the three
TPP−malonate monoesters is likely to be multifactorial. Steric
hindrance from the bulky TPP moiety may contribute to the
negligible hydrolysis of TPP3−malonate.42 However, steric
hindrance alone is unlikely to explain the difference in
hydrolysis between TPP6−malonate and TPP11−malonate
and suggests that hydrophobic binding may also be a
contributing factor.43 Overall, this suggests an undecyl
monoester of the dicarboxylate is favorable due to its more
rapid enzymatic hydrolysis.
Uptake and Hydrolysis of TPP−Malonate Monoesters
by Mitochondria. We next assessed if the malonate
monoesters were accumulated by incubating the compounds
with energized, isolated mitochondria. To do this, we pelleted
the mitochondria and measured the uptake into the organelle
of the TPP−malonate ester by RP-HPLC, in comparison to a
simple alkyl-TPP molecule (either isoamyl-TPP or propyl-
TPP, to avoid elution overlap) to confirm mitochondrial
energization (Figures 3A and S4). A typical RP-HPLC trace
from the incubation of the TPP11−malonate monoester with
rat heart mitochondria (RHM) is shown, which illustrates that
both TPP11−malonate and propyl-TPP were taken up by
energized mitochondria and that this uptake was prevented by
abolishing the membrane potential with the uncoupler FCCP
(Figure 3A). Similar experiments showed that TPP11−
malonate was also accumulated by energized rat liver
mitochondria (RLM) but that neither TPP3−malonate nor
TPP6−malonate were accumulated by energized mitochondria
(Figure S4A and B). Small differences in the levels of
accumulation between liver and heart mitochondria likely
reflect the differences in composition and volume between
mitochondria from different tissues and cell types.44 An
analysis of the supernatant after pelleting the mitochondria
showed that while TPP11−malonate was taken up into the
mitochondria, TPP3− and TPP6−malonate remained in the
supernatant (Figure S4B). Furthermore, the addition of the
tetraphenylborate (TPB) lipophilic anion, which often
facilitates the mitochondrial uptake of TPP cations,12,45 had
little effect on the uptake of TPP3− or TPP6−malonate,
confirming a lack of accumulation in mitochondria (Figure
S4C).
The quantification of the uptake of the esters into
mitochondria is shown in Figure 3B and C. These findings
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are consistent with our earlier works, which showed that TPP
cations linked to carboxylic acids required the incorporation of
significant hydrophobicity to counteract the polarity of the
carboxylic acid and enable membrane permeation.27,28 We
conclude that only TPP11−malonate is accumulated by
mitochondria due to its greater hydrophobicity.
In addition to TPP11−malonate, its hydrolysis product 11-
OH undecyl-TPP was also detected in mitochondria, and its
level increased over time in RLM (Figures 3D and S4). At the
same time, the amount of 11-OH undecyl-TPP in the
supernatant was relatively unchanged (Figures 3D and S4).
In heart mitochondria, where the esterase activity is lower
(both contaminating and intramitochondrial),46 a large
accumulation of TPP11−malonate occurs (peak 8 in Figures
3A and S4A), but the levels of its hydrolysis product, 11-OH
undecyl-TPP (peak 7 in Figures 3A and S4A), in the
mitochondrial pellet are far lower than in liver mitochondria
(Figures 3D and S4).
We next measured the release of malonate within
mitochondria incubated with TPP−malonate monoesters.
Only TPP11−malonate released malonate within mitochondria,
consistent with its uptake by energized mitochondria (Figure
3E). That TPP11−malonate uptake occurs before its hydrolysis
is confirmed by the concentration of malonate observed in the
mitochondrial pellet. Even if TPP11−malonate was hydrolyzed
to completion outside of mitochondria, the concentration of
malonate in the supernatant would be 10 μM, a concentration
that would lead to mitochondrial malonate levels less than 50
pmol/mg of protein,31 far lower than the ∼250 pmol/mg of
protein achieved by TPP11−malonate (Figure 3E). TPP11−
malonate could deliver malonate intramitochondrially in both
liver and heart mitochondria; however, the levels in heart
mitochondria were significantly lower over these short-
duration incubations, mirroring the lower hydrolysis within
RHM (Figure 3E).
To test whether the malonate released from TPP11−
malonate could elicit the intended biological effect and inhibit
SDH, we measured the production of the ROS hydrogen
peroxide (H2O2), which is driven by SDH-dependent succinate
oxidation and RET in isolated heart mitochondria (Figure 3F).
TPP11−malonate significantly reduced ROS production from
succinate oxidation compared to equivalent concentrations of
its cleaved products, 11-OH undecyl-TPP (Figure 3F) or
malonate (Figure S4D), directly added to mitochondria. Thus,
TPP11−malonate significantly accumulates in mitochondria
and hydrolyzes to release malonate, which subsequently
inhibits SDH. As only TPP11−malonate accumulated and
hydrolyzed to release malonate in mitochondria, neither
TPP3−malonate nor TPP6−malonate were tested in sub-
sequent analyses.
Figure 4. TPP11−malonate mitochondrial accumulation is pH gradient-dependent. (A−C) Uptake of TPP11−malonate ± nigericin (100 nM) in
(A) RLM and (B) RHM. (C) Accumulation of TPP11−malonate-derived compounds normalized to propyl-TPP ± nigericin. All data represent the
mean ± SEM, n = 3. The statistical significance was assessed by two-way ANOVA with Dunnett’s correction for multiple comparisons (compared
to the relevant control group), where *p < 0.05 .
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Uptake of TPP−Malonate Monoesters is Enhanced by
the pH Gradient. We next explored whether the mitochon-
drial uptake of TPP11−malonate was enhanced due to the
interaction of the carboxylic acid with the pH gradient (Figure
1). To do this, we assessed its uptake by energized
mitochondria in the presence of the K+/H+ exchanger
nigericin, which will abolish the pH gradient across the
mitochondrial inner membrane but increase the membrane
potential.47 The uptake of TPP11−malonate was compared
with the simple alkyl-TPP cation propyl-TPP as an internal
control within the same incubation, which will only respond to
changes in the membrane potential and will be unaffected by
alterations in the pH gradient. Nigericin led to an increase in
the uptake of propyl-TPP due to the elevated membrane
potential but did not affect the uptake of TPP11−malonate by
RLM or RHM (Figure 4A and B). This lack of an effect of
nigericin was likely due to the increased uptake of TPP11−
malonate due to the elevated membrane potential being
balanced by the decrease in uptake due to the abolition of the
pH gradient.27,28 To test this possibility, we compared the ratio
of the uptake of TPP11−malonate to propyl-TPP in the
presence of nigericin (Figure 4C). Normalizing the uptake of
TPP11−malonate to that of propyl-TPP enabled us to correct
for the effects of membrane potential on uptake. Nigericin
decreased the membrane potential-corrected uptake of TPP11−
malonate (Figure 4C). Therefore, the uptake of TPP11−
malonate is dependent on both the mitochondrial membrane
potential and the pH gradients, similarly to other TPP-
conjugated carboxylic acids,27,28 and thus may increase its
selectivity to mitochondrial delivery.
Uptake of TPP11−Malonate by Cells and Release of
Malonate. As TPP11−malonate was an effective delivery
vector in isolated mitochondria, we next assessed its effects in a
cell model. We first exposed cells to a range of concentrations
of TPP11−malonate for 24 h and found no difference in the
levels of cell death compared to a vehicle (EtOH) control
(Figure S5A), suggesting that TPP−dicarboxylate esters can be
safely used in cells without significant adverse effects. Next, to
Figure 5. Malonate delivery by TPP11−malonate in cells. (A−C) C2C12 cells were incubated with TPP11−malonate (10 μM) before extraction of
the cell pellet (A) and supernatant (B), and measurement of TPP-linked compounds (A and B) and malonate in the pellet (C) by LC-MS/MS
(mean ± SEM, n = 3).
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assess the uptake of TPP11−malonate and its hydrolysis in cells
and in vivo, we set up a LC-MS/MS assay for both TPP11−
malonate and its hydrolysis product 11-OH undecyl-TPP
(Figure S6). We incubated C2C12 mouse myoblasts with
TPP11−malonate for up to 4 h and measured the levels of the
parent compound and hydrolysis products measured by LC-
MS/MS in the cells and supernatant. The uptake of TPP11−
malonate into cells was rapid, with the compound found in the
cell pellet even at the earliest time point possible (Figure 5A).
The levels of TPP11−malonate within cells increased over 1 h
before plateauing. The hydrolysis product, 11-OH undecyl-
TPP, mirrored TPP11−malonate within the cellular pellet. This
differed when HeLa cells were incubated with TPP11−
malonate, as the levels of TPP11−malonate continued to rise
but 11-OH undecyl-TPP plateaued (Figure S5B). TPP11−
malonate was stable to hydrolysis in the extracellular medium
(Figure 5B), suggesting TPP11−malonate is taken up and
hydrolyzed within the cells.
In addition, the intracellular levels of malonate after TPP11−
malonate treatment were significantly elevated compared to
cells treated with 11-OH undecyl-TPP alone; thus, TPP11−
malonate effectively delivers malonate to cells (Figure 5C).
While the levels of malonate in mitochondria cannot be
accurately measured directly, due to the extremely rapid
redistribution of metabolites during mitochondrial isolation,
previous work has shown the mitochondrial selectivity of TPP
cations,16,48 suggesting that the malonate delivered intra-
cellularly is likely to be delivered within mitochondria.
Furthermore, TPP11−malonate could also affect cellular
respiration, confirming that the compound was entering
mitochondria in cells and inhibiting mitochondrial function
(Figure S5C).
Uptake of TPP11−Malonate In Vivo. Next, we inves-
tigated the usefulness of TPP esters as a dicarboxylate delivery
strategy, by testing TPP11−malonate in vivo. C57BL/6J mice
were injected with a bolus of TPP11−malonate (1.6 mg/kg) via
the tail vein and killed either 5 or 40 min after injection, and
Figure 6. In vivo uptake of TPP11−malonate. (A−E) C57BL/6J mice were tail-vein-injected with 1.6 mg/kg of TPP11−malonate as a 100 μL bolus
in 0.9% saline. Mice were culled and organs harvested 5 or 40 min after injection. The liver (A), heart (B), kidney (C), brain (D), and blood (E)
were extracted and analyzed for TPP-linked compounds and malonate by LC-MS/MS (mean ± SEM, n = 3). The time “0” point values are from
control, saline-injected animals.
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then, the tissues were snap frozen for later extraction and
analysis by LC-MS/MS. TPP11−malonate, 11-OH undecyl-
TPP, and malonate were all detected in the analyzed tissues,
with high levels 5 min after injection, which decreased 40 min
after injection (Figure 6A−D). This suggests that TPP11−
malonate accumulated in different tissues, wherein it was
hydrolyzed to release malonate within the mitochondria of the
cells. The achieved levels of the compound were significantly
higher in the kidney (Figure 6C) compared to the other
tissues, suggesting a tissue distribution comparable to other
TPP-linked compounds in vivo.22,49 Furthermore, as the main
route of clearance of TPP-linked compounds is via renal
excretion,22 this will also contribute to the accumulation of the
TPP-linked compounds in the kidney. The blood levels of
TPP11−malonate and its hydrolysis products are low (Figure
6E), consistent with the rapid distribution of TPP-linked
Figure 7. Schematic of TPP11−malonate as a mitochondrial delivery strategy in vivo. Abbreviations: OMM, outer mitochondrial membrane; IMM,
inner mitochondrial membrane; IMS, intermembrane space; SDH, succinate dehydrogenase; Δψm, mitochondrial membrane potential; DIC,
mitochondrial dicarboxylate carrier.
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compounds from the circulation into tissues.22,49 Overall, here
we have developed a mitochondria-targeted malonate prodrug,
which is able to deliver malonate selectively to mitochondria in
cells and in vivo (Figure 7). This work confirms that a
mitochondria-targeted prodrug approach is possible and
facilitates the delivery and release of dicarboxylates within
mitochondria.
■ DISCUSSION
Attaching a small molecule dicarboxylate to TPP led to a
mitochondria membrane potential-dependent and pH gra-
dient-dependent uptake for malonate as an example drug
molecule. Due to the pKa of malonate being particularly low
(pKa1 = 2.83 and pKa2 = 5.69),
50 it provided challenging
properties as a test cargo for the mitochondria-targeted
delivery strategy. Despite this, TPP11−malonate could deliver
malonate in mitochondria of cells in vitro and in vivo. The use
of an undecyl linker region facilitated uptake across biological
membranes by increasing the hydrophobicity, which also
enhanced ester hydrolysis. Finally, the elevated hydrophobicity
may also increase the association of the compound with
biological membranes, thereby increasing the compound’s pKa
at the crossing site,51 enhancing the rate of membrane
permeation. These findings confirmed that the TPP11-
monoester is a viable approach for the delivery of
dicarboxylates to mitochondria.
The shorter linker regions between malonate and the TPP
moiety had a significant impact on the accumulation of the
molecule across the mitochondrial inner membrane. Recent
reports have shown that modifying the TPP-targeting group by
replacing hydrogens in the phenyl groups with methyl groups
(T*PP+) improves the efficiency of cation uptake into
mitochondria.52,53 Increasing the hydrophobicity, the solvent-
accessible surface area and volume per charge (Vpc) of the
cation improved accumulation into mitochondria.20,52 The
increase in linker length in our work also has the potential for
increasing the solvent-accessible surface area and Vpc in
addition to the increased hydrophobic interactions with the
membrane; thus, the uptake of TPP11−malonate with the
increased linker regions is likely to be multifactorial. The
complex biophysical interactions of TPP−dicarboxylate esters
and biological membranes warrant further study in order to
gain greater insight into their molecular characteristics and to
aid future drug design.
TPP cations have been utilized previously to achieve
selective mitochondrial accumulation of therapies and probes.
However, their permanent conjugation to the bioactive
molecule can present problems with hindering the drug’s
activity as well as promoting redistribution and potential
removal from the cell due to the action of the TPP cation.
Here, by conjugating the dicarboxylate to the TPP cation via a
cleavable ester bond, the release of the bioactive compound in
its native form is enabled, thus leaving its active site interaction
unchanged. Furthermore, it enables the TPP-linker region to
be metabolized and excreted independently of the bioactive
drug. This has the potential added benefit of extending the
exposure time of the drug without increasing the delivered
dose or dose frequency.
By developing this cleavable mitochondria-targeting plat-
form, this opens up the potential to selectively target particular
isoforms of enzymes within mitochondria. As a number of
enzymes within mitochondria are also found in the cytosol,
differentiating the effects of a treatment with nontargeted
dicarboxylate prodrugs may be challenging due to it acting
upon both the cytosolic and mitochondrial forms. By attaching
the active dicarboxylate compound via an ester bond to a TPP
moiety, similarly to TPP11−malonate, this would enable the
assessment of the active compound’s effect directly on
mitochondria, with limited impact on the cytosolic isoform.
Therefore, in addition to being a potential therapeutic
platform, TPP−dicarboxylate esters may also be useful probe
molecules to selectively uncover the roles of mitochondrial
proteins within disease.
■ CONCLUSIONS
Mitochondria are central to the development of numerous
pathologies. Mitochondria-targeted molecules have thus far led
to insights into mitochondrial biology and new therapeutic
approaches. Currently, a constraint on mitochondria-targeted
molecules has been that the targeted molecule is permanently
attached to the targeting platform, thus hindering activity
within the mitochondria. Here, we have developed a
mitochondria-targeted malonate monoester, which overcomes
the problems described above by extensively accumulating in
mitochondria, wherein it releases the cargo of interest. This
suggests that further dicarboxylates could be delivered in a
similar manner. Overall, we have shown that TPP−
dicarboxylate monoesters are a promising strategy to deliver
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